Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action

被引：0

作者：

Bykova, Aleksandra ^{[1
,2
]}

Serova, Maria ^{[1
,3
]}

Chashkina, Maria ^{[1
]}

Kosharnaya, Raisa ^{[4
]}

Salpagarova, Zukhra ^{[5
]}

Andreev, Denis ^{[1
]}

Giverts, Ilya ^{[6
,7
]}

机构：

[1] Sechenov Univ, IM Sechenov First Moscow State Med Univ, NV Sklifosovsky Inst Clin Med, Dept Cardiol Funct & Ultrasound Diagnost, Bolshaya Pirogovskaya St 6-1, Moscow 119991, Russia

[2] Russian Acad Sci, Sci Res Inst Syst Anal, Dept Med Informat, Moscow, Russia

[3] City Clin Hosp 1, Moscow State Healthcare Inst, Dept Surg Treatment Complex Rhythm Disorders & Pac, Moscow, Russia

[4] Endocrinol Res Ctr, Dept Cardiol & Vasc Surg, Moscow, Russia

[5] Med Ctr ATLAS, Dept Cardiol, Moscow, Russia

[6] Maimonides Hosp, Dept Internal Med, New York, NY USA

[7] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA USA

来源：

CARDIAC FAILURE REVIEW | 2024年 / 10卷

关键词：

Glucagon-like peptide-1 receptor agonists; heart failure with preserved ejection fraction; diabetes; obesity; atrial fibrillation; coronary artery; disease; arterial hypertension; TYPE-2; DIABETES-MELLITUS; MAJOR CARDIOVASCULAR EVENTS; GLUCOSE-LOWERING AGENTS; GLP-1; RECEPTOR; ATRIAL-FIBRILLATION; DOUBLE-BLIND; CONTROLLED-TRIAL; ADIPOSE-TISSUE; LIRAGLUTIDE; EXENATIDE;

D O I：

10.15420/cfr.2024.06

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This review examines the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on different heart failure phenotypes with preserved ejection fraction (HFpEF). Traditional heart failure treatment modalities have shown limited success in improving outcomes for patients with HFpEF, but new evidence suggests that GLP-1RAs could be beneficial. The positive effects of GLP-1RAs are likely due to their ability to reduce systemic inflammation, enhance metabolism and directly affect the cardiovascular system, addressing critical aspects of HFpEF pathology. However, the exact impact of GLP-1RAs on clinical outcomes for different HFpEF phenotypes is still unclear. This review highlights both the potential benefits and the current limitations of GLP-1RA therapy, suggesting a careful approach for their application in clinical practice.

引用

页数：8

共 82 条

[61] The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, Anna
Jelsing, Jacob
Baquero, Arian F.
Hecksher-Sorensen, Jacob
Cowley, Michael A.
Dalboge, Louise S.
Hansen, Gitte
Grove, Kevin L.
Pyke, Charles
Raun, Kirsten
Schaffer, Lauge
Tang-Christensen, Mads
Verma, Saurabh
Witgen, Brent M.
Vrang, Niels
Knudsen, Lotte Bjerre
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (10) : 4473 - 4488
[62] Recent updates on GLP-1 agonists: Current advancements & challenges
Sharma, Dilip
Verma, Suril
Vaidya, Shivani
Kalia, Kiran
Tiwari, Vinod
[J]. BIOMEDICINE & PHARMACOTHERAPY, 2018, 108 : 952 - 962
[63] Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis
Shi, Wence
Zhang, Wenchang
Zhang, Da
Ren, Ge
Wang, Pengfei
Gao, Lihua
Chen, Haonan
Ding, Chunhua
[J]. HEART RHYTHM, 2021, 18 (07) : 1090 - 1096
[64] The effect of glucagon-like peptide 1 on cardiovascular risk
Sivertsen, Jacob
Rosenmeier, Jaya
Holst, Jens J.
Vilsboll, Tina
[J]. NATURE REVIEWS CARDIOLOGY, 2012, 9 (04) : 209 - 222
[65] Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men
Skov, Jeppe
Dejgaard, Anders
Frokiaer, Jorgen
Holst, Jens Juul
Jonassen, Thomas
Rittig, Soren
Christiansen, Jens Sandahl
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (04) : E664 - E671
[66] Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D.
McMurray, J. J., V
Claggett, B.
de Boer, R. A.
DeMets, D.
Hernandez, A. F.
Inzucchi, S. E.
Kosiborod, M. N.
Lam, C. S. P.
Martinez, F.
Shah, S. J.
Desai, A. S.
Jhund, P. S.
Belohlavek, J.
Chiang, C-E
Borleffs, C. J. W.
Comin-Colet, J.
Dobreanu, D.
Drozdz, J.
Fang, J. C.
Alcocer-Gamba, M. A.
Al Habeeb, W.
Han, Y.
Cabrera Honorio, J. W.
Janssens, S. P.
Katova, T.
Kitakaze, M.
Merkely, B.
O'Meara, E.
Saraiva, J. F. K.
Tereshchenko, S. N.
Thierer, J.
Vaduganathan, M.
Vardeny, O.
Verma, S.
Pham, V. N.
Wilderang, U.
Zaozerska, N.
Bachus, E.
Lindholm, D.
Petersson, M.
Langkilde, A. M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, : 1089 - 1098
[67] Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
Stratton, IM
Adler, AI
Neil, HAW
Matthews, DR
Manley, SE
Cull, CA
Hadden, D
Turner, RC
Holman, RR
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258): : 405 - 412
[68] Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits
Sudo, Mitsumasa
Li, Yuxin
Hiro, Takafumi
Takayama, Tadateru
Mitsumata, Masako
Shiomi, Masashi
Sugitani, Masahiko
Matsumoto, Taro
Hao, Hiroyuki
Hirayama, Atsushi
[J]. ATHEROSCLEROSIS, 2017, 265 : 283 - 291
[69] Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
Sun, Feng
Wu, Shanshan
Wang, Jing
Guo, Shuxia
Chai, Sanbao
Yang, Zhirong
Li, Lishi
Zhang, Yuan
Ji, Linong
Zhan, Siyan
[J]. CLINICAL THERAPEUTICS, 2015, 37 (01) : 225 - 241
[70] Study of the Potential Association of Adipose Tissue GLP-1 Receptor with Obesity and Insulin Resistance
Vendrell, Joan
El Bekay, Rajaa
Peral, Belen
Garcia-Fuentes, Eduardo
Megia, Anna
Macias-Gonzalez, Manuel
Fernandez Real, Jose
Jimenez-Gomez, Yolanda
Escote, Xavier
Pachon, Gisela
Simo, Rafael
Selva, David M.
Malagon, Maria M.
Tinahones, Francisco J.
[J]. ENDOCRINOLOGY, 2011, 152 (11) : 4072 - 4079

← 1 2 3 4 5 6 7 8 9 →